Literature DB >> 18711222

Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study.

Ruth C Campbell1, Xuemei Sui, Gerasimos Filippatos, Thomas E Love, Christy Wahle, Paul W Sanders, Ali Ahmed.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is associated with increased mortality in patients with heart failure (HF). However, its association with hospitalization in HF patients has not been well studied.
METHODS: Of 7788 patients in the Digitalis Investigation Group trial, 3527 had CKD, defined by an estimated glomerular filtration rate (GFR) <60 ml/min/1.73 m(2) body surface area (BSA). Propensity scores for CKD were calculated using a multivariable logistic regression model and used to match 2399 pairs of patients with and without CKD. Matched Cox regression analyses were used to estimate association of CKD with outcomes.
RESULTS: All-cause hospitalization occurred in 1636 (rate, 4233/10,000 person-years) and 1587 (rate, 3733/10,000 person-years) patients respectively, with and without CKD (matched hazard ratio [HR] for CKD, 1.18, 95% confidence interval [CI], 1.08-1.29; P < 0.0001). Matched HR for cardiovascular and HF hospitalization were respectively 1.17 (95% CI, 1.06-1.28, P = 0.002) and 1.28 (95% CI, 1.13-1.45, P < 0.0001). Compared to GFR >or=60 ml/min/1.73 m(2) BSA, HR for all-cause hospitalization for GFR 45-59 and <45 ml/min/1.73 m(2) BSA were respectively 1.04 (95% CI, 0.94-1.16; P = 0.422) and 1.58 (95% CI, 1.34-1.87; P < 0.0001). Similarly, HR for all-cause death for GFR 45-59 and <45 ml/min/1.73 m(2) BSA were respectively 1.03 (95% CI, 0.90-1.18; P = 0.651) and 1.70 (95% CI, 1.40-2.07; P < 0.0001). Matched HR for death due to cardiovascular causes and progressive HF were respectively 1.24 (95% CI, 1.09-1.40; P = 0.001) and 1.42 (95% CI, 1.16-1.72; P = 0.001).
CONCLUSION: CKD was associated with increased mortality and hospitalization in ambulatory patients with chronic HF, which increased progressively with worsening kidney function.

Entities:  

Mesh:

Year:  2008        PMID: 18711222      PMCID: PMC2721423          DOI: 10.1093/ndt/gfn445

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  24 in total

1.  On principles for modeling propensity scores in medical research.

Authors:  Donald B Rubin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-12       Impact factor: 2.890

2.  Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.

Authors:  Peter M Rothwell
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

Review 3.  The severe cardiorenal syndrome: 'Guyton revisited'.

Authors:  Lennart G Bongartz; Maarten Jan Cramer; Pieter A Doevendans; Jaap A Joles; Branko Braam
Journal:  Eur Heart J       Date:  2004-11-30       Impact factor: 29.983

Review 4.  Estimating causal effects from large data sets using propensity scores.

Authors:  D B Rubin
Journal:  Ann Intern Med       Date:  1997-10-15       Impact factor: 25.391

5.  Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.

Authors:  Tom D J Smilde; Dirk J van Veldhuisen; Gerjan Navis; Adriaan A Voors; Hans L Hillege
Journal:  Circulation       Date:  2006-10-02       Impact factor: 29.690

6.  Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study.

Authors:  Kirsten Bibbins-Domingo; Glenn M Chertow; Linda F Fried; Michelle C Odden; Anne B Newman; Stephen B Kritchevsky; Tamara B Harris; Suzanne Satterfield; Steven R Cummings; Michael G Shlipak
Journal:  Arch Intern Med       Date:  2006-07-10

7.  Race and renal impairment in heart failure: mortality in blacks versus whites.

Authors:  Grace L Smith; Michael G Shlipak; Edward P Havranek; Frederick A Masoudi; William M McClellan; JoAnne M Foody; Saif S Rathore; Harlan M Krumholz
Journal:  Circulation       Date:  2005-03-15       Impact factor: 29.690

8.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

Authors:  Ali Ahmed; Michael W Rich; Thomas E Love; Donald M Lloyd-Jones; Inmaculada B Aban; Wilson S Colucci; Kirkwood F Adams; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2005-12-08       Impact factor: 29.983

9.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.

Authors:  Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge
Journal:  Eur Heart J       Date:  2006-05-18       Impact factor: 29.983

10.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

View more
  19 in total

1.  Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions.

Authors:  Jeffrey M Testani; Brian D McCauley; Jennifer Chen; Michael Shumski; Richard P Shannon
Journal:  Cardiology       Date:  2010-08-03       Impact factor: 1.869

Review 2.  Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.

Authors:  Min-Seok Kim; Ju-Hee Lee; Eung Ju Kim; Dae-Gyun Park; Sung-Ji Park; Jin Joo Park; Mi-Seung Shin; Byung Su Yoo; Jong-Chan Youn; Sang Eun Lee; Sang Hyun Ihm; Se Yong Jang; Sang-Ho Jo; Jae Yeong Cho; Hyun-Jai Cho; Seonghoon Choi; Jin-Oh Choi; Seong Woo Han; Kyung Kuk Hwang; Eun Seok Jeon; Myeong-Chan Cho; Shung Chull Chae; Dong-Ju Choi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

3.  The Number of GT(n) Repeats in the Hemeoxygenase-1 Gene Promoter is Increased in Pediatric Heart Failure but is Unrelated to Renal, Antioxidant and Anti-inflammatory Markers.

Authors:  Sherif Sayed; Naglaa K Idriss; Andrew Blann; Hayam G Sayyed; D M Raafat; Doaa Fouad; M S K Tawfeek
Journal:  Pediatr Cardiol       Date:  2015-03-31       Impact factor: 1.655

4.  Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure.

Authors:  Jeffrey M Testani; Brian D McCauley; Stephen E Kimmel; Richard P Shannon
Journal:  Am J Cardiol       Date:  2010-11-04       Impact factor: 2.778

Review 5.  Epidemiology and outcome of the cardio-renal syndrome.

Authors:  Dinna N Cruz; Mihai Gheorghiade; Alberto Palazzuoli; Alberto Palazuolli; Claudio Ronco; Sean M Bagshaw
Journal:  Heart Fail Rev       Date:  2011-11       Impact factor: 4.214

6.  Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study.

Authors:  Khalil Murad; David C Goff; Timothy M Morgan; Gregory L Burke; Traci M Bartz; Jorge R Kizer; Sarwat I Chaudhry; John S Gottdiener; Dalane W Kitzman
Journal:  JACC Heart Fail       Date:  2015-07       Impact factor: 12.035

Review 7.  Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling.

Authors:  Rosita Zakeri; John C Burnett; S Jeson Sangaralingham
Journal:  Clin Chim Acta       Date:  2014-12-12       Impact factor: 3.786

8.  Epidemiology of chronic kidney disease in heart failure.

Authors:  Ali Ahmed; Ruth C Campbell
Journal:  Heart Fail Clin       Date:  2008-10       Impact factor: 3.179

9.  Heart-kidney interaction: epidemiology of cardiorenal syndromes.

Authors:  Dinna N Cruz; Sean M Bagshaw
Journal:  Int J Nephrol       Date:  2010-12-29

Review 10.  Cardiorenal Syndrome and Heart Failure-Challenges and Opportunities.

Authors:  Haran Yogasundaram; Mark C Chappell; Branko Braam; Gavin Y Oudit
Journal:  Can J Cardiol       Date:  2019-04-12       Impact factor: 6.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.